RECRUITING

Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)

Talk to us

Conditions

Non-Traumatic Subarachnoid HemorrhageBeta-adrenergic blockadeCardiac dysfunctionInflammation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To determine the effect of early metoprolol administration after non-traumatic subarachnoid hemorrhage (SAH).

Official Title

Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)

Quick Facts

Study Start:2024-09-23
Study Completion:2029-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06569212

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * \>18 years of age
  2. * Neuro-imaging confirmed non-traumatic subarachnoid hemorrhage
  1. * Traumatic cause of subarachnoid hemorrhage (e.g. fall, motor vehicle accident, other blunt trauma) as this is a different mechanism of hemorrhage.
  2. * Other forms of traumatic or non-traumatic intracranial bleed including intracerebral hemorrhage (ICH), subdural hemorrhage, epidural hemorrhage
  3. * Pregnancy (as the study medication, metoprolol, has FDA Pregnancy Category C rating)
  4. * Unstable vital signs not amenable to beta-1 adrenergic receptor inhibitor (B1ARi) administration including:
  5. * Systolic blood pressure \< 80 mmHg not stabilized on vasopressor medications
  6. * Heart rate \< 50 bpm associated with hypotension
  7. * Patients requiring vasopressor agents due to hypotension (SBP \<80 mmHg)
  8. * Other vital sign exclusion at the discretion of the treatment team
  9. * Previous history of severe heart failure (Stage C or D Heart Failure and/or NYHA Class III or IV)
  10. * Patient or legally authorized representative unwilling to provide informed consent

Contacts and Locations

Study Contact

Madeleine Puissant, MD, PhD
CONTACT
2076613660
Madeleine.Puissant@mainehealth.org
Christine Lord
CONTACT
Christine.Lord@mainehealth.org

Principal Investigator

Madeleine Puissant, MD, PhD
PRINCIPAL_INVESTIGATOR
MaineHealth

Study Locations (Sites)

MaineHealth
Portland, Maine, 04012
United States

Collaborators and Investigators

Sponsor: Madeleine Puissant

  • Madeleine Puissant, MD, PhD, PRINCIPAL_INVESTIGATOR, MaineHealth

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-23
Study Completion Date2029-09

Study Record Updates

Study Start Date2024-09-23
Study Completion Date2029-09

Terms related to this study

Keywords Provided by Researchers

  • Beta-adrenergic blockade
  • Cardiac dysfunction
  • Inflammation

Additional Relevant MeSH Terms

  • Non-Traumatic Subarachnoid Hemorrhage